Evaluation of 3 Hour Infusion of Paclitaxel Plus Cisplatin and 5-Fluorouracil in Patients with Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)

Closed

Phase

Accrual

100%

Published

Abbreviated Title

Advanced, Recurrent, or Metastatic

Activated

11/01/2000

Closed

05/15/2003

Participants

NCORP, Members, Medical Oncologists

Research committees

Head and Neck Cancer

Treatment

Cisplatin 5-Fluorouracil Paclitaxel

Eligibility Criteria Expand/Collapse

Pts. must have histologically proven SCCHN that is met. at dx or persisted, met. or recurred following definitive surgery and/or RT (* 28 days prior to reg.). Pts. whose only measurable dz is within a prior RT port must have clearly prog. dz prior to reg. Newly diag., non-met. dz are not eligible. Pts. must have measurable or non-measurable dz; pts. must not have received prior chemo for recurrent or newly diagnosed met dz. Pts. w/ neuropathy - sensory * Grade 2 are not eligible.

Publication Information Expand/Collapse

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2006

A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group Study 0007

FP Worden;J Moon;W Samlowski;JI Clark;SR Dakhil;S Williamson;SG Urba;J Ensley;MH Hussain Cancer 107(2):319-327

2004

A phase II evaluation of a 3-hour infusion of paclitaxel (P), cisplatin (CDDP) & 5-fluorouracil (5FU) in patients with advanced or recurrent squamous cell carcinoma of the head and neck (SCCHN). A Southwest Oncology Group (SWOG) study

FP Worden;J Moon;W Samlowski;J Clark;SR Dakhil;SA Taylor;SG Urba;M Hussain Proc of the American Society of Clinial Oncology 23:489 (#5512)